{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:55:25Z","timestamp":1792612525811,"version":"4.5.0"},"reference-count":17,"publisher":"Japanese Society for Pediatric Endocrinology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pediatr Endocrinol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1297\/cpe.26.1","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T17:08:21Z","timestamp":1485882501000},"page":"1-7","source":"Crossref","is-referenced-by-count":18,"title":["Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves\u2019 disease"],"prefix":"10.1297","volume":"26","author":[{"given":"Kie","family":"Yasuda","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Tachibana","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Namba","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan"},{"name":"Department of Pediatrics, Japan Community Health Care Organization Osaka Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan"},{"name":"Department of Pediatrics, Itami Municipal Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"125","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Rivkees, SA. The treatment of Graves disease in children. J Pediatr Endocrinol Metab 2006;19: 1095\u2013111.","DOI":"10.1515\/JPEM.2006.19.9.1095"},{"key":"2","unstructured":"2. Rivkees, SA, Sklar, C, Freemark, M. Clinical review 99: The management of Graves disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998;83: 3767\u201376."},{"key":"3","unstructured":"3. Japanese Society for Pediatric Endocrinology2008 Guideline for the drug treatment of childhood onset Graves\u2019 disease. Nippon Shonika Gakkai Zasshi 2008;112: 946\u201352 (In Japanese)."},{"key":"4","unstructured":"4. Japan Thyroid Association 2011 Guideline for the drug treatment of Graves\u2019 diseases. 1st ed. Tokyo: Nankodo; 2011. p. 135-140."},{"key":"5","unstructured":"5. Japanese Society for Pediatric Endocrinology2016 Guideline for the treatment of childhood onset Graves\u2019 disease. http:\/\/jspe.umin.jp\/medical\/files\/gravesdisease_guideline2016.pdf. (accessed: April 23, 2016)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sato, H, Minagawa, M, Sasaki, N, Sugihara, S, Kazukawa, I, Minamitani, K, et al. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves disease: efficacy and adverse reactions during initial treatment and long-term outcome. J Pediatr Endocrinol Metab 2011;24: 257\u201363.","DOI":"10.1515\/jpem.2011.194"},{"key":"7","unstructured":"7. Japan Thyroid Association 2011 Guideline for the drug Treatment of Graves\u2019 diseases. 1st ed. Tokyo: Nankodo; 2011. p. 41-50."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sato, H, Sasaki, N, Minamitani, K, Minagawa, M, Kazukawa, I, Sugihara, S, et al. Higher dose of methimazole causes frequent adverse effects in the management of Graves disease in children and adolescents. J Pediatr Endocrinol Metab 2012;25: 863\u20137.","DOI":"10.1515\/jpem-2012-0138"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nakamura, H, Noh, JY, Itoh, K, Fukata, S, Miyauchi, A, Hamada, N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves disease. J Clin Endocrinol Metab 2007;92: 2157\u201362.","DOI":"10.1210\/jc.2006-2135"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Sato, S, Noh, JY, Sato, S, Suzuki, M, Yasuda, S, Matsumoto, M, et al. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg\/day and methimazole 30 mg\/day as initial therapy for Graves disease patients with moderate to severe hyperthyroidism. Thyroid 2015;25: 43\u201350.","DOI":"10.1089\/thy.2014.0084"},{"key":"11","unstructured":"11. Reinwein, D, Benker, G, Lazarus, JH, Alexander, WD, European Multicenter Study Group on Antithyroid Drug TreatmentA prospective randomized trial of antithyroid drug dose in Graves disease therapy. J Clin Endocrinol Metab 1993;76: 1516\u201321."},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Takata, K, Kubota, S, Fukata, S, Kudo, T, Nishihara, E, Ito, M, et al. Methimazole-induced agranulocytosis in patients with Graves disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 2009;19: 559\u201363.","DOI":"10.1089\/thy.2008.0364"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Cooper, DS, Goldminz, D, Levin, AA, Ladenson, PW, Daniels, GH, Molitch, ME, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 1983;98: 26\u20139.","DOI":"10.7326\/0003-4819-98-1-26"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hamerschlak, N, Maluf, E, Biasi Cavalcanti, A, Avezum J\u00fanior, A, Eluf-Neto, J, Passeto Falc\u00e3o, R, et al. Incidence and risk factors for agranulocytosis in Latin American countriesthe Latin Study: a multicenter study. Eur J Clin Pharmacol 2008;64: 921\u20139.","DOI":"10.1007\/s00228-008-0513-7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Minamitani, K, Oikawa, J, Wataki, K, Kashima, K, Hoshi, M, Inomata, H, et al. A report of three girls with antithyroid drug-induced agranulocytosis: retrospective analysis of 18 cases aged 15 years or younger reported between 1995 and 2009. Clin Pediatr Endocrinol 2011;20: 39\u201346.","DOI":"10.1297\/cpe.20.39"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Ohye, H, Minagawa, A, Noh, JY, Mukasa, K, Kunii, Y, Watanabe, N, et al. Antithyroid drug treatment for graves disease in children: a long-term retrospective study at a single institution. Thyroid 2014;24: 200\u20137.","DOI":"10.1089\/thy.2012.0612"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Tamai, H, Takaichi, Y, Morita, T, Komaki, G, Matsubayashi, S, Kuma, K, et al. Methimazole-induced agranulocytosis in Japanese patients with Graves disease. Clin Endocrinol (Oxf) 1989;30: 525\u201330.","DOI":"10.1111\/j.1365-2265.1989.tb01424.x"}],"container-title":["Clinical Pediatric Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/26\/1\/26_2016-0016\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T05:27:46Z","timestamp":1498368466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/26\/1\/26_2016-0016\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1297\/cpe.26.1","relation":{},"ISSN":["0918-5739","1347-7358"],"issn-type":[{"value":"0918-5739","type":"print"},{"value":"1347-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}